ALX Oncology (ALXO) awards 700,000 stock options to its Chief Medical Officer

Rhea-AI Filing Summary

ALX Oncology Holdings Inc reported that Chief Medical Officer Barbara Klencke received a grant of stock options representing 700,000 shares of the company’s stock. This is recorded as a derivative security transaction categorized as a grant, award, or other acquisition.

According to the vesting terms, one-fourth of the shares subject to the option vest on February 25, 2027, and the remaining portion vests in equal monthly installments of 1/48th thereafter. Following this grant, she is shown as holding 700,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Klencke Barbara

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	700,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 700,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klencke Barbara

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.07	03/03/2026		A		700,000		(1)	03/02/2036	Common Stock	700,000	$0	700,000	D

Explanation of Responses:

1. One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter.

	/s/ Shelly Pinto, by power of attorney	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ALX Oncology (ALXO) report for Barbara Klencke?

ALX Oncology reported that Chief Medical Officer Barbara Klencke received a grant of stock options for 700,000 shares. The transaction is classified as a derivative security acquisition categorized as a grant, award, or other acquisition, and is held as a direct ownership position.

How many stock options were granted to the ALX Oncology (ALXO) Chief Medical Officer?

Barbara Klencke, Chief Medical Officer of ALX Oncology, was granted stock options covering 700,000 shares. This entire amount is reported as directly owned following the transaction, reflecting a single option grant recorded on the reported transaction date in the Form 4 filing.

What is the vesting schedule for Barbara Klencke’s ALX Oncology (ALXO) stock options?

One-fourth of the shares subject to the option vest on February 25, 2027. The remaining shares then vest in equal monthly installments of 1/48th thereafter, creating a gradual vesting schedule over time as disclosed in the accompanying footnote.

How is the ALX Oncology (ALXO) option grant to Barbara Klencke classified?

The option grant to Barbara Klencke is classified as a derivative security transaction with code “A.” It is described as a grant, award, or other acquisition, reflecting an award of stock options rather than an open-market purchase or sale of existing common shares.

What ownership type is reported for Barbara Klencke’s ALX Oncology (ALXO) stock options?

The 700,000 stock options granted to Barbara Klencke are reported as directly owned. The filing lists the ownership code as “D,” indicating direct ownership, with total derivative securities following the transaction equal to the full granted amount.